Berzosertib

Generic Name: Berzosertib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₅N_₅O_₃S

CAS Number: 1232416-25-9

Unique Ingredient Identifier: L423PRV3V3

Background: Berzosertib (VX-970) has been used in trials studying the treatment of Ovarian Neoplasms, Ovarian Serous Tumor, Adult Solid Neoplasm, Advanced Solid Tumor, and Advanced Solid Neoplasm, among others.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors

Phase 1

Recruiting

Conditions: HRD Cancer
SCLC
Advanced Solid Tumors

Interventions: Drug: Berzosertib
Drug: Sacituzumab Govitecan

First Posted Date: 2021-04-01

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 120

Registration Number: NCT04826341

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers

Phase 1

Recruiting

Conditions: SCLC
Advanced Solid Tumor
High Grade Neuroendocrine Cancers
Small Cell Cancer

Interventions: Drug: Lurbinectedin
Drug: Berzosertib

First Posted Date: 2021-03-17

Last Posted Date: 2024-12-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 120

Registration Number: NCT04802174

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer

Phase 1

Active, not recruiting

Conditions: Lung Non-Small Cell Squamous Carcinoma
Stage IV Lung Cancer AJCC v8

Interventions: Drug: Berzosertib
Procedure: Biospecimen Collection
Drug: Carboplatin
Procedure: Computed Tomography
Drug: Gemcitabine Hydrochloride
Procedure: Magnetic Resonance Imaging
Biological: Pembrolizumab

First Posted Date: 2020-01-02

Last Posted Date: 2024-07-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 12

Registration Number: NCT04216316

Locations: 🇺🇸
UM Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida, United States
🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸
USC Norris Oncology/Hematology-Newport Beach, Newport Beach, California, United States

and more 31 locations

Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer

Phase 1

Active, not recruiting

Conditions: Localized Breast Carcinoma
Recurrent Breast Carcinoma
Triple-Negative Breast Carcinoma
Bilateral Breast Carcinoma
HER2-Negative Breast Carcinoma

Interventions: Drug: Berzosertib
Procedure: Biospecimen Collection
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Radiation: Radiation Therapy

First Posted Date: 2019-08-12

Last Posted Date: 2024-11-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 42

Registration Number: NCT04052555

Locations: 🇺🇸
University of Texas Medical Branch, Galveston, Texas, United States
🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
Farmington Health Center, Farmington, Utah, United States

and more 11 locations

Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs

Phase 2

Active, not recruiting

Conditions: Limited Stage Lung Small Cell Carcinoma
Platinum-Resistant Lung Small Cell Carcinoma
Platinum-Sensitive Lung Small Cell Carcinoma
Extensive Stage Lung Small Cell Carcinoma
Extrapulmonary Small Cell Neuroendocrine Carcinoma
Recurrent Lung Small Cell Carcinoma

Interventions: Drug: Berzosertib
Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Topotecan Hydrochloride

First Posted Date: 2019-04-01

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 104

Registration Number: NCT03896503

Locations: 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
USC Norris Oncology/Hematology-Newport Beach, Newport Beach, California, United States
🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

and more 30 locations

Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer

Phase 2

Active, not recruiting

Conditions: Metastatic Gastroesophageal Junction Adenocarcinoma
Clinical Stage III Gastric Cancer AJCC v8
Clinical Stage IV Gastric Cancer AJCC v8
Unresectable Gastroesophageal Junction Adenocarcinoma
Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
Metastatic Gastric Adenocarcinoma
Unresectable Gastric Adenocarcinoma

Interventions: Drug: Berzosertib
Procedure: Computed Tomography Assisted Biopsy
Procedure: Endoscopic Biopsy
Drug: Irinotecan
Procedure: Magnetic Resonance Imaging

First Posted Date: 2018-08-22

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 14

Registration Number: NCT03641313

Locations: 🇺🇸
The University of Kansas Cancer Center - Olathe, Olathe, Kansas, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States

and more 28 locations

M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2

Active, not recruiting

Conditions: Stage IV Prostate Cancer AJCC v8
Metastatic Prostate Carcinoma
Castration-Resistant Prostate Carcinoma

Interventions: Drug: Berzosertib
Drug: Carboplatin
Drug: Docetaxel
Other: Laboratory Biomarker Analysis

First Posted Date: 2018-05-08

Last Posted Date: 2024-11-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 130

Registration Number: NCT03517969

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States

and more 20 locations

Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 1

Active, not recruiting

Conditions: Metastatic Ovarian Carcinoma
Platinum-Sensitive Ovarian Carcinoma
Recurrent Ovarian Carcinoma
Stage IV Fallopian Tube Cancer AJCC v6 and v7
Stage IV Ovarian Cancer AJCC v6 and v7
Stage IV Primary Peritoneal Cancer AJCC v7
Ovarian Endometrioid Tumor
Recurrent Primary Peritoneal Carcinoma
Metastatic Primary Peritoneal Carcinoma
Recurrent Fallopian Tube Carcinoma

Interventions: Drug: Berzosertib
Drug: Carboplatin
Drug: Gemcitabine Hydrochloride
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study

First Posted Date: 2015-12-11

Last Posted Date: 2024-12-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 31

Registration Number: NCT02627443

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States

and more 11 locations

Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2

Active, not recruiting

Conditions: Recurrent Fallopian Tube Carcinoma
Recurrent Ovarian Carcinoma
Ovarian Serous Tumor
Recurrent Primary Peritoneal Carcinoma

Interventions: Drug: Berzosertib
Drug: Gemcitabine
Drug: Gemcitabine Hydrochloride

First Posted Date: 2015-11-04

Last Posted Date: 2024-08-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 70

Registration Number: NCT02595892

Locations: 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
University of Virginia Cancer Center, Charlottesville, Virginia, United States

and more 14 locations

M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Phase 1

Active, not recruiting

Conditions: Metastatic Pancreatic Carcinoma
Refractory Pancreatic Carcinoma
Stage IV Pancreatic Cancer AJCC v8
Refractory Colorectal Carcinoma
Metastatic Lung Small Cell Carcinoma
Stage III Pancreatic Cancer AJCC v8
Stage IV Colorectal Cancer AJCC v8
Stage IV Lung Cancer AJCC v8
Unresectable Colorectal Carcinoma
Unresectable Lung Small Cell Carcinoma

Interventions: Drug: Berzosertib
Procedure: Biopsy Specimen
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Irinotecan Hydrochloride

First Posted Date: 2015-11-04

Last Posted Date: 2024-12-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 66

Registration Number: NCT02595931

Locations: 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸
Stanford Cancer Institute Palo Alto, Palo Alto, California, United States

and more 20 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy